Principia

Humans have been predicting eclipses for thousands of years, but it's harder than you might think

Retrieved on: 
Monday, April 17, 2023

But it turns out calculating exactly when and where we can watch an eclipse in its full glory can be surprisingly hard.

Key Points: 
  • But it turns out calculating exactly when and where we can watch an eclipse in its full glory can be surprisingly hard.
  • Read more:
    Since the late 19th century, adventurous female 'eclipse chasers' have contributed to science in Australia

Watching the Sun and the Moon

    • Being so dominant in the sky, the Sun and the Moon were the most captivating celestial bodies for ancient cultures to observe.
    • While the Sun’s movement is quite simple, the Moon moves across the sky with much more complexity.
    • During a lunar eclipse, where Earth blocks sunlight that would otherwise illuminate a full moon, the dimmed Moon takes on a bloody hue.

The not-so-mythical Saros cycle

    • This 18-year cycle, which can persist as a sequence for over a thousand years, is now known as a Saros cycle.
    • The Saros cycle represents how long it takes for the Sun-Earth-Moon system to return to almost exactly the same triangular configuration.
    • This is much more frequent than an 18-year Saros cycle, and is possible because multiple repeating Saros sequences overlap at once (roughly a dozen), each offset by at least six months.
    • After about a thousand years, when one long-term Saros sequence ends, another will begin with slightly different timing.

From antiquity to modern day

    • Yes, if we are talking about lunar eclipses, and perhaps even partial solar eclipses.
    • That is, they wouldn’t have predicted that 18 years later (567 BCE) a total solar eclipse was visible in what is now the United States.
    • But significantly, it could not predict total solar eclipses at a precise place on Earth – just their timing.
    • Entering the modern era of science, the first true prediction of a total solar eclipse (both in time and location) occurred in 1715.

Dodge Construction Network Acquires Principia Consulting, Expanding Dodge Advisory Services’ Capabilities

Retrieved on: 
Tuesday, October 11, 2022

Dodge Construction Network (Dodge or the Company), backed by affiliates of Clearlake Capital Group and Symphony Technology Group, today announced the acquisition of Principia Consulting (Principia), a data, research and consulting firm.

Key Points: 
  • Dodge Construction Network (Dodge or the Company), backed by affiliates of Clearlake Capital Group and Symphony Technology Group, today announced the acquisition of Principia Consulting (Principia), a data, research and consulting firm.
  • Principia will be integrated with Dodge Advisory Services, supported by a dedicated team of industry experts providing industry research, forecasting, and analysis.
  • Industry participants looking to leverage Dodge Advisory Services and Principia for growth should contact Patty Morin, [email protected] .
  • With over a century of industry experience, Dodge Construction Network is the catalyst for modern commercial construction.

Arcellx Appoints Olivia Ware to Board of Directors

Retrieved on: 
Monday, May 16, 2022

FOSTER CITY, Calif., May 16, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Olivia Ware to its Board of Directors. Ms. Ware, a successful executive, brings a wealth of knowledge from her more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management.

Key Points: 
  • "On behalf of our entire Board, I'd like to thank Rusty for his many contributions to Arcellx as both a private and publicly traded biotech company.
  • "Olivia's deep industry and commercialization expertise will be an invaluable addition to the existing depth of experience on our Board.
  • Arcellx's lead product candidate, CART-ddBCMA, has the potential to be a meaningful treatment option for patients diagnosed with multiple myeloma, an incurable disease," said Olivia Ware.
  • Ms. Ware replaces Lewis T. "Rusty" Williams, M.D., co-founder, chairman and chief executive officer of Walking Fish Therapeutics, who has served on Arcellx's Board of Directors since 2019.

Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as Chief Financial Officer

Retrieved on: 
Wednesday, April 6, 2022

Alumis, a precision immunology company incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointments of Sara Klein as general counsel and secretary and John R. Schroer as chief financial officer.

Key Points: 
  • Alumis, a precision immunology company incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointments of Sara Klein as general counsel and secretary and John R. Schroer as chief financial officer.
  • John R. Schroer joins Alumis from ArsenalBio where he served as chief financial officer.
  • Prior to that role, Mr. Schroer served as chief financial officer and treasurer at Translate Bio.
  • From 2009 to December 2013, he served as president and chief investment officer at Schroer Capital, LP, a financial services company that he founded.

Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer

Retrieved on: 
Thursday, November 18, 2021

Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of Puneet S. Arora, M.D.

Key Points: 
  • Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of Puneet S. Arora, M.D.
  • As a highly regarded physician-scientist and drug developer, Puneets experience in inflammation and immunology will be instrumental to Lassen as we initiate our clinical program for LASN01, our first-in-class anti-IL-11R antibody, said Mark Barrett Chief Executive Officer of Lassen Therapeutics.
  • Dr. Arora managed clinical development for lead programs including early translational development and proof of concept through late development and regulatory submissions.
  • Lassen is pursuing compelling targets and novel mechanisms of action with the potential to result in important new therapeutics for patients with limited treatment options.

BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer

Retrieved on: 
Wednesday, November 17, 2021

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).

Key Points: 
  • BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).
  • We are thrilled to welcome two seasoned industry leaders into the BioAge management team, said Kristen Fortney, Ph.D., CEO of BioAge.
  • Goldstein comes to BioAge with extensive strategic financial experience in the biopharmaceutical sector.
  • He joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the companys growth strategies as well as operational finance and business development.

Entos Announces Scientific Advisory Board Additions

Retrieved on: 
Thursday, September 9, 2021

Entos, Inc. (Entos or the Company), the creator of a cutting-edge platform combining AI-driven technology and automated synthesis to design small-molecule therapeutics, today announced that it has appointed Jack Taunton, Professor of Cellular Molecular Pharmacology at University of California, San Francisco, and Ken Brameld, Senior Advisor for Samsara Biocapital, to the Companys Scientific Advisory Board.

Key Points: 
  • Entos, Inc. (Entos or the Company), the creator of a cutting-edge platform combining AI-driven technology and automated synthesis to design small-molecule therapeutics, today announced that it has appointed Jack Taunton, Professor of Cellular Molecular Pharmacology at University of California, San Francisco, and Ken Brameld, Senior Advisor for Samsara Biocapital, to the Companys Scientific Advisory Board.
  • The addition of Jack and Ken to our team brings further drug discovery and pharmaceutical industry experience to our already stellar Scientific Advisory Board, said Tom Miller, co-founder and CEO of Entos.
  • Prof. Taunton and Dr. Brameld will join Nobel Prize winner Frances Arnold, MIT Assistant Professor of Engineering Connor Coley, and Director in Chemical Biology Therapeutics at Novartis, Derek Lowe, on the Companys Scientific Advisory Board.
  • The Scientific Advisory Board provides Entos with unparalleled expertise and valuable guidance as the Company expands and applies its differentiated technology to overcome the high risk and long timelines associated with traditional therapeutic discovery.

Global Atopic Dermatitis Drugs Market 2021-2026 by Drug Class, Route of Administration, Geography, Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, August 20, 2021

The Global Atopic Dermatitis Drugs Market is estimated to be USD 7.2 Bn in 2021 and is expected to reach USD 10 Bn by 2026, growing at a CAGR of 6.8%.

Key Points: 
  • The Global Atopic Dermatitis Drugs Market is estimated to be USD 7.2 Bn in 2021 and is expected to reach USD 10 Bn by 2026, growing at a CAGR of 6.8%.
  • The major factor driving the growth of the global atopic dermatitis drugs market is the growing incidence of food allergies exacerbating atopic dermatitis, increasing emphasis on systematic therapies, increasing pharmacological products in developing countries, and the rise in awareness regarding the availability of treatments for the disease.
  • Furthermore, the rising adoption of targeted treatments such as Eucrisa and Dupixent is propelling the market.
  • By Drug Class, the market is classified into biologics, calcineurin inhibitors, corticosteroids, and pde4 inhibitors.

Sanofi completes Principia Biopharma Inc. acquisition

Retrieved on: 
Monday, September 28, 2020

Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans, will be and similar expressions.

Key Points: 
  • Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans, will be and similar expressions.
  • Any material effect of COVID-19 on any of the foregoing could also adversely impact Sanofi and Principia.
  • This situation is changing rapidly and additional impacts may arise of which Sanofi and Principia are not currently aware and may exacerbate other previously identified risks.
  • The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Sanofi and Principia do not undertake any obligation to update or revise any forward-looking information or statements.

Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.

Retrieved on: 
Tuesday, September 22, 2020

Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans, will be and similar expressions.

Key Points: 
  • Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans, will be and similar expressions.
  • Any material effect of COVID-19 on any of the foregoing could also adversely impact Sanofi and Principia.
  • This situation is changing rapidly and additional impacts may arise of which Sanofi and Principia are not currently aware and may exacerbate other previously identified risks.
  • Additional copies may be obtained for free by contacting Sanofi at [email protected] or on Sanofis website at https://en.sanofi.com/investors .